ArticleCancer discovery2020
Leukemia Cell of Origin Influences Apoptotic Priming and Sensitivity to LSD1 Inhibition.
Open access · bronzeAbstract read
In one paragraph
Article in Cancer discovery, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 43 citations in OpenAlex.
- The KDM-family inhibitor JIB-04 sensitizes AML cells to venetoclax by inducing a ferroptosis-like phenotype.Blood neoplasia · 2026Article
- Genomic Subtype Influences BH3 Mimetic Drug Sensitivity and Synergy with Cytotoxic Chemotherapeutics in T-cell Acute Lymphoblastic Leukemia.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Article
- A synergistic interaction between PRMT5 and LSD1 inhibitors in AML.Science advances · 2026Article
- Ontogeny Dictates Oncogenic Potential, Lineage Hierarchy, and Therapy Response in Pediatric Leukemia.Cancer discovery · 2026Article
- Therapeutic targeting of chromatin alterations in leukemia and solid tumors.International journal of cancer · 2026Review
- Epigenetic Targeting in Myeloid Malignancies.Advances in experimental medicine and biology · 2026Review
- The oncogenic role of ecotropic viral integration site 1 in hematological malignancies: mechanisms of activation and leukemogenesis.Frontiers in immunology · 2026Review
- Chromatin Regulatory Targets for Anticancer Therapeutics.Chemical reviews · 2025Review
- The histone-methyltransferase DOT1L cooperates with LSD1 to control cell division in blast-phase MPN.Leukemia · 2025Article
- Developmental stage modulates the prognostic impact of RAS pathway mutations in AML patients undergoing Allo-HSCT.Annals of hematology · 2025Article
- Hematopoietic Stem Cell Hierarchies as Novel Biomarkers of Drug Response in Myelodysplastic Syndromes and Acute Myeloid Leukemia.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Review
- Sensitization of Non-M3 Acute Myeloid Leukemia Blasts to All-Trans Retinoic Acid by the LSD1 Inhibitor Tranylcypromine: TRANSATRA Phase I Study.European journal of haematology · 2025Article
- Perturbing LSD1 and WNT rewires transcription to synergistically induce AML differentiation.Nature · 2025Article
- Article
- Review
- Acute resistance to BET inhibitors remodels compensatory transcriptional programs via p300 coactivation.Blood · 2025Article
- FLT3-Mutated Leukemic Stem Cells: Mechanisms of Resistance and New Therapeutic Targets.Cancers · 2024Review
- Preclinical efficacy of targeting epigenetic mechanisms in AML with 3q26 lesions and EVI1 overexpression.Leukemia · 2024Article
- Therapeutic targeting Tudor domains in leukemia via CRISPR-Scan Assisted Drug Discovery.Science advances · 2024Article
- EVI1-mediated Programming of Normal and Malignant Hematopoiesis.HemaSphere · 2023Review
Corrections and comments
- Commented on by
Authors and funding
27 authors at 6 institutions in 3 countries.
Sheng F CaiHuman Oncology & Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID https://orcid.org/0000-0002-2708-887X
S Haihua ChuDepartment of Pediatric Oncology, Dana-Farber Cancer Institute and Division of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts.
Aaron D GoldbergLeukemia Service, Department of Medicine, and Center for Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID https://orcid.org/0000-0002-2892-2643
Salma ParvinDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
Richard P KocheCenter for Epigenetics Research, Memorial Sloan Kettering Cancer Center, New York, New York.
Jacob L GlassLeukemia Service, Department of Medicine, and Center for Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, New York.
Eytan M SteinLeukemia Service, Department of Medicine, and Center for Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, New York.
Martin S TallmanLeukemia Service, Department of Medicine, and Center for Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, New York.
Filiz SenHematopathology Diagnostic Service, Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
Christopher A FamulareLeukemia Service, Department of Medicine, and Center for Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, New York.
Monica CusanUniversity Hospital, Ludwig Maximilian University Munich, Munich, Germany.
Chun-Hao HuangCancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Chun-Wei ChenDepartment of Systems Biology, Beckman Research Institute, City of Hope, Duarte, California.ORCID https://orcid.org/0000-0002-8737-6830
Lihua ZouCenter for Epigenetics Research, Memorial Sloan Kettering Cancer Center, New York, New York.
Keith B CordnerHuman Oncology & Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Nicole L DelGaudioHuman Oncology & Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Vidushi DuraniHuman Oncology & Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Mitali KiniHuman Oncology & Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Madison RexHuman Oncology & Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Helen S TianHuman Oncology & Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID https://orcid.org/0000-0001-8097-1082
Johannes ZuberResearch Institute of Molecular Pathology (IMP), Vienna, Austria.
Timour BaslanCancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Scott W LoweCancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID https://orcid.org/0000-0002-5284-9650
Hugh Y RienhoffImago Biosciences, Inc., San Francisco, California.
Anthony LetaiDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
Ross L Levine *Human Oncology & Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York. scott_armstrong@dfci.harvard.edu leviner@mskcc.org.
Scott A Armstrong *Department of Pediatric Oncology, Dana-Farber Cancer Institute and Division of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts. scott_armstrong@dfci.harvard.edu leviner@mskcc.org.
Memorial Sloan Kettering Cancer Center · USDana-Farber Cancer Institute · USBD Biosciences (United States) · USCity Of Hope National Medical Center · USLudwig-Maximilians-Universität München · DEResearch Institute of Molecular Pathology · AT
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4MVIRAL TRANSACTIVATIONP01CA013106 · NCI · COLD SPRING HARBOR LABORATORY · PI Camila dos Santos · 1985 to 2026
$116.8MTissue BankP01CA108671 · NCI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI Ronald Hoffman · 2006 to 2026
$82.0MTYROSINE KINASE ONCOGENESIS IN MYELOID LEUKEMIAP01CA066996 · NCI · DANA-FARBER CANCER INSTITUTE · PI SCOTT A ARMSTRONG · 1996 to 2026
$52.5MSynergistic role of signaling and epigenetics in leukemic transformationR35CA197594 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Ross L Levine · 2017 to 2026
$11.4MMolecular pathogenesis of MLL-AF4 leukemiasR01CA140575 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI ARMSTRONG, SCOTT A · 2010 to 2014
$1.7MNCI NIH HHS P01 CA013106NCI NIH HHS P01 CA066996NCI NIH HHS P01 CA108671NCI NIH HHS P30 CA008748NCI NIH HHS R01 CA140575NCI NIH HHS R35 CA197594
Abstract
The cell of origin of oncogenic transformation is a determinant of therapeutic sensitivity, but the mechanisms governing cell-of-origin-driven differences in therapeutic response have not been delineated. Leukemias initiating in hematopoietic stem cells (HSC) are less sensitive to chemotherapy and highly express the transcription factor
Indexed as
ApoptosisGene Expression Regulation, LeukemicHistone DemethylasesHumansLeukemiaTranscription FactorsHistone DemethylasesKDM1A protein, humanTranscription Factors
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.